DiamiR Biosciences Corp. (DIMR)

DiamiR Biosciences will go public soon, but the exact IPO date is still unknown.

Stock Price: Pending

IPO price not available yet

DiamiR Biosciences Income Statement

Financials in millions USD. Fiscal year is June - May.

Millions USD. Fiscal year is Jun - May.

Year	2023	2022
Revenue	1.13	1.44
Revenue Growth (YoY)	-21.71%	-
Gross Profit	1.13	1.44
Selling, General & Admin	0.92	0.44
Research & Development	1.36	1.16
Operating Expenses	2.29	1.6
Operating Income	-1.16	-0.16
Interest Expense / Income	0.11	0.17
Pretax Income	-1.27	-0.32
Income Tax	0.05	-
Net Income	-1.32	-0.32
Free Cash Flow	-0.21	0.12
Gross Margin	100.00%	100.00%
Operating Margin	-102.63%	-10.78%
Profit Margin	-116.88%	-22.29%
Free Cash Flow Margin	-18.38%	8.36%
EBITDA	-1.07	-0.03
EBITDA Margin	-94.68%	-2.19%
Depreciation & Amortization	0.09	0.12
EBIT	-1.16	-0.16
EBIT Margin	-102.63%	-10.78%

Source: IPO financials are sourced from S-1 and S-1/A filings submitted to the Securities and Exchange Commission (SEC).